Management of Multiple Sclerosis in the Breastfeeding Mother

Saneea Almas, Jesse Vance, Teresa Baker, Thomas Hale

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers.

Original languageEnglish (US)
Article number6527458
JournalMultiple Sclerosis International
Volume2016
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Breast Feeding
Multiple Sclerosis
Mothers
Pharmaceutical Preparations
Myelitis
Therapeutics
Safety
Relapsing-Remitting Multiple Sclerosis
Interferon-beta
Immunologic Factors
Immunosuppressive Agents
Autoimmune Diseases
Adrenal Cortex Hormones
Milk
Nursing
Monoclonal Antibodies
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Management of Multiple Sclerosis in the Breastfeeding Mother. / Almas, Saneea; Vance, Jesse; Baker, Teresa; Hale, Thomas.

In: Multiple Sclerosis International, Vol. 2016, 6527458, 01.01.2016.

Research output: Contribution to journalReview article

Almas, Saneea ; Vance, Jesse ; Baker, Teresa ; Hale, Thomas. / Management of Multiple Sclerosis in the Breastfeeding Mother. In: Multiple Sclerosis International. 2016 ; Vol. 2016.
@article{f2b2b454cba0478986449f26f696b761,
title = "Management of Multiple Sclerosis in the Breastfeeding Mother",
abstract = "Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers.",
author = "Saneea Almas and Jesse Vance and Teresa Baker and Thomas Hale",
year = "2016",
month = "1",
day = "1",
doi = "10.1155/2016/6527458",
language = "English (US)",
volume = "2016",
journal = "Multiple Sclerosis International",
issn = "2090-2654",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Management of Multiple Sclerosis in the Breastfeeding Mother

AU - Almas, Saneea

AU - Vance, Jesse

AU - Baker, Teresa

AU - Hale, Thomas

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers.

AB - Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers.

UR - http://www.scopus.com/inward/record.url?scp=84998559021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998559021&partnerID=8YFLogxK

U2 - 10.1155/2016/6527458

DO - 10.1155/2016/6527458

M3 - Review article

C2 - 26966579

AN - SCOPUS:84998559021

VL - 2016

JO - Multiple Sclerosis International

JF - Multiple Sclerosis International

SN - 2090-2654

M1 - 6527458

ER -